Microscale hydrogel fibers could enable imaging inside tiny tissue structures
Peer-Reviewed Publication
This month, we're turning our attention to Breast Cancer Awareness Month, a time dedicated to increasing awareness, supporting early detection, and highlighting the ongoing research shaping the future of breast cancer treatment and prevention.
Updates every hour. Last Updated: 23-Oct-2026 06:17 ET (23-Oct-2026 10:17 GMT/UTC)
Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for adult patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) locally advanced or metastatic breast cancer following induction treatment. This marks a major milestone and offers new hope for individuals living with this challenging subtype of advanced breast cancer.
Compelled by disparities in breast cancer outcomes, the Keck School of Medicine of USC’s Department of Population and Public Health Sciences and Novartis have joined forces in a pioneering collaboration to support medically underserved communities in Los Angeles County with the goal of eliminating barriers to screening and access. While Black women in the U.S. have higher screening rates for breast cancer than white women, the mortality rate for Black women with breast cancer is about 40% higher than white women —a disparity that is not yet fully understood but has been linked to a lack of access to timely, high-quality care and resources. Native American and Hispanic women also face significant disparities in breast cancer screening, often resulting in later-stage diagnoses compared to white women. The Keck School of Medicine of USC and Novartis bring complementary strengths to this collaboration, combining USC’s regional expertise in breast cancer health disparities and population sciences with Novartis’s experience and capabilities in advancing breast cancer care through collaboration and a passion for transforming patient care. The collaboration with Novartis will focus on the early detection of breast cancer, specifically reaching those in communities where access to breast cancer screening and quality care has been limited.USC’s researchers will examine the everyday obstacles that stand between women and timely care, including insurance coverage, language barriers, and access to reliable transportation.